Celgene Corp

CELG-Q

NASDAQ:CELG

108.24
0.11 (0.10%)
Celgene Corporation is an American biotechnology company that discovers, develops and commercializes medicines for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey.
More at Wikipedia

Analysis and Opinions about CELG-Q

Signal
Opinion
Expert
HOLD
HOLD
April 25, 2018

A disappointment, having fallen on a number of missteps including negative trial results and management issues. With biotechs, the odds of getting a drug out of trials into production is small. So, it's best to have a stable of drugs and some of them will go through. Doesn't know if this is at a bottom here, but it should do well long-term. Carries an attractive below-10x earnings multiple.

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
April 25, 2018

A disappointment, having fallen on a number of missteps including negative trial results and management issues. With biotechs, the odds of getting a drug out of trials into production is small. So, it's best to have a stable of drugs and some of them will go through. Doesn't know if this is at a bottom here, but it should do well long-term. Carries an attractive below-10x earnings multiple.

SELL STRENGTH
SELL STRENGTH
April 2, 2018

It broke down in a lousy earnings report late last year. It broke its trend line, and more importantly the level of support at $97 has been broken. There is a lot of air or space now below this price. He is concerned about the look of it from a technical perspective. It might pop back up to its previous support level.

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
April 2, 2018

It broke down in a lousy earnings report late last year. It broke its trend line, and more importantly the level of support at $97 has been broken. There is a lot of air or space now below this price. He is concerned about the look of it from a technical perspective. It might pop back up to its previous support level.

TOP PICK
TOP PICK
March 21, 2018

Sticking with it. Valuations are too attractive to ignore. All they need are a few winning drugs and to offer proper guidance. Let's see some of their trials succeed--even good results will do. Their pipeline is too robust to stay at 8.5x forwarded earning. But management needs to regain credibility. (Analysts' target of $116.08)

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
March 21, 2018

Sticking with it. Valuations are too attractive to ignore. All they need are a few winning drugs and to offer proper guidance. Let's see some of their trials succeed--even good results will do. Their pipeline is too robust to stay at 8.5x forwarded earning. But management needs to regain credibility. (Analysts' target of $116.08)

PAST TOP PICK
PAST TOP PICK
March 21, 2018

(A Top Pick May 10/17, Down 26%) Was once a widely-owned, then despised, stock. New management came in, then there was a downrgade, then their Crohn's disease drug missed, then received an FDA letter for a mass drug is incomplete, which almost never happens. They've made a lot of mistakes in a short time. It still enjoys near-20% EPS growth. They have a dozen phase-two drugs in progress--a deep pipeline--but management has disappointed. That said, he continues to have faith in CELG.

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
March 21, 2018

(A Top Pick May 10/17, Down 26%) Was once a widely-owned, then despised, stock. New management came in, then there was a downrgade, then their Crohn's disease drug missed, then received an FDA letter for a mass drug is incomplete, which almost never happens. They've made a lot of mistakes in a short time. It still enjoys near-20% EPS growth. They have a dozen phase-two drugs in progress--a deep pipeline--but management has disappointed. That said, he continues to have faith in CELG.

TOP PICK
TOP PICK
March 20, 2018

Many growth opportunities but took some hits, falling from $150. Great opportunity now. FDA approval is coming up, so there's potential. 10.5x earnings. Could grow 15-20%. (Analysts' target of $116.32)

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
March 20, 2018

Many growth opportunities but took some hits, falling from $150. Great opportunity now. FDA approval is coming up, so there's potential. 10.5x earnings. Could grow 15-20%. (Analysts' target of $116.32)

BUY
BUY
March 13, 2018

Boasts 10-11x forward earnings with a 15% growth rate. FDA trial approvals would increase investor confidence further, but they have a good pipeline of products. Likes it longer term.

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
March 13, 2018

Boasts 10-11x forward earnings with a 15% growth rate. FDA trial approvals would increase investor confidence further, but they have a good pipeline of products. Likes it longer term.

PAST TOP PICK
PAST TOP PICK
January 15, 2018

(A Top Pick April 19/17. Down 14%.) This shot up to about $140, but a key new drug application was denied. That was followed by them announcing that their 3rd quarter was a little more difficult. They still have a plethora of new drug applications, and is still one of the hottest stocks in the sector. A very solid company.

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
January 15, 2018

(A Top Pick April 19/17. Down 14%.) This shot up to about $140, but a key new drug application was denied. That was followed by them announcing that their 3rd quarter was a little more difficult. They still have a plethora of new drug applications, and is still one of the hottest stocks in the sector. A very solid company.

PAST TOP PICK
PAST TOP PICK
December 7, 2017

(A Top Pick Nov 18/16. Down 16%.) Recently collapsed a bit, but still likes the name. Trading at 12X Forward Earnings with a 19% growth rate. That’s a .63 PEG ratio. They toned down guidance for 2020, and the concern is that they are going to be relying on their top cancer drug. Has been buying shares slowly. A cheap biotech name.

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
December 7, 2017

(A Top Pick Nov 18/16. Down 16%.) Recently collapsed a bit, but still likes the name. Trading at 12X Forward Earnings with a 19% growth rate. That’s a .63 PEG ratio. They toned down guidance for 2020, and the concern is that they are going to be relying on their top cancer drug. Has been buying shares slowly. A cheap biotech name.

WAIT
WAIT
November 16, 2017

One of the larger biotech companies. The big drop last month was due to a halt in one of their trials where they were developing what looked like a pretty good drug which would have been a big market. He would stay away for another month or so, but longer-term, it is a pretty good company with a portfolio of good drugs in development and good drugs in the market.

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
November 16, 2017

One of the larger biotech companies. The big drop last month was due to a halt in one of their trials where they were developing what looked like a pretty good drug which would have been a big market. He would stay away for another month or so, but longer-term, it is a pretty good company with a portfolio of good drugs in development and good drugs in the market.

PAST TOP PICK
PAST TOP PICK
November 13, 2017

(A Top Pick April 19/17. Down 18%.) Was one of the hottest stocks in the medical space. They have a plethora of new products in front of the FDA. It caught a cliff when 3 events happened. It was getting close to his target price of $150. One of the major analysts cut their price target which knocked it into the $130 range. FDA didn’t approve one of the new drugs knocking the price down into the $120 range. Missed a little on the 3rd quarter, so it dropped into the $100 range. He still likes it and is still buying.

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
November 13, 2017

(A Top Pick April 19/17. Down 18%.) Was one of the hottest stocks in the medical space. They have a plethora of new products in front of the FDA. It caught a cliff when 3 events happened. It was getting close to his target price of $150. One of the major analysts cut their price target which knocked it into the $130 range. FDA didn’t approve one of the new drugs knocking the price down into the $120 range. Missed a little on the 3rd quarter, so it dropped into the $100 range. He still likes it and is still buying.

PAST TOP PICK
PAST TOP PICK
November 10, 2017

(A Top Pick Nov 30/16. Down 14%.) Reported earlier this month. Just prior to reporting, took a phase 3 drug out of the pipeline, that had a lot of promise. It was a drug that treated Crohn’s disease. It will build back some of the confidence, but it will take time. The return opportunities are good enough to continue holding the position.

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
November 10, 2017

(A Top Pick Nov 30/16. Down 14%.) Reported earlier this month. Just prior to reporting, took a phase 3 drug out of the pipeline, that had a lot of promise. It was a drug that treated Crohn’s disease. It will build back some of the confidence, but it will take time. The return opportunities are good enough to continue holding the position.

BUY
BUY
October 20, 2017

This is revisiting old highs, which is a very bullish sign. In this case, it actually broke above its old highs. The current correction seems very healthy as long as it continues making higher lows. Add to your position, but keep a Stop at around $110.

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
October 20, 2017

This is revisiting old highs, which is a very bullish sign. In this case, it actually broke above its old highs. The current correction seems very healthy as long as it continues making higher lows. Add to your position, but keep a Stop at around $110.

PAST TOP PICK
PAST TOP PICK
September 20, 2017

(A Top Pick Oct 4/16. Up 38%.) One of the outstanding growth stocks in the US medical field. They have a plethora of new drugs coming out. Sales are growing at about 25% per annum. With the current earnings, the target price could move into the $165-$170 due to the growth rate. The company is more likely to surprise on the upside and another $1 of earnings could give you a $20-$25 a share. This could be a $200 stock. Still a Buy.

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
September 20, 2017

(A Top Pick Oct 4/16. Up 38%.) One of the outstanding growth stocks in the US medical field. They have a plethora of new drugs coming out. Sales are growing at about 25% per annum. With the current earnings, the target price could move into the $165-$170 due to the growth rate. The company is more likely to surprise on the upside and another $1 of earnings could give you a $20-$25 a share. This could be a $200 stock. Still a Buy.

TOP PICK
TOP PICK
September 19, 2017

This has done extremely well. It is growing quickly. Has a good pipeline with 4 drugs that he believes could be $1 billion or more in revenue. The biggest property they own is Revlimid. They concentrate on cancer treating drugs. Not inexpensive, but is reasonably priced. Thinks that next year they will do $8 a share in earnings, less than 20X, and growing at a rapid rate. (Analysts’ price target is $156.)

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
September 19, 2017

This has done extremely well. It is growing quickly. Has a good pipeline with 4 drugs that he believes could be $1 billion or more in revenue. The biggest property they own is Revlimid. They concentrate on cancer treating drugs. Not inexpensive, but is reasonably priced. Thinks that next year they will do $8 a share in earnings, less than 20X, and growing at a rapid rate. (Analysts’ price target is $156.)

PAST TOP PICK
PAST TOP PICK
September 14, 2017

(Top Pick Feb 22/17, Up 19%). They have a blood cancer drug. They are testing it on all kinds of other indications. They have the ability to double the revenues based on their existing products. It is the more growthy component of his portfolio.

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
September 14, 2017

(Top Pick Feb 22/17, Up 19%). They have a blood cancer drug. They are testing it on all kinds of other indications. They have the ability to double the revenues based on their existing products. It is the more growthy component of his portfolio.

Showing 31 to 45 of 90 entries